

Reference:	FOI.21175 - 21177.26
Subject:	Treatments
Date of Request:	29 July 2026

Your request and our response

Where the figures in the tables have been replaced with an asterisk (*), Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

FOI.21175

1. How many patients were treated in **total** regardless of diagnosis with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table overleaf, the number of patients treated with the listed medications, for any condition, during the period 1 April to 30 June 2026.

Drug Name	Total number of patients treated regardless of diagnosis
Adalimumab	618
Abrocitinib	*
Apremilast	30
Baricitinib	43
Bimekizumab	10
Brodalumab	*
Certolizumab Pegol	39
Deucravacitinib	0
Dupilumab	158
Etanercept	170
Guselkumab	*
Infliximab	226
Ixekizumab	5
Lebrikizumab	*
Nemolizumab	*
Risankizumab	170
Secukinumab	102
Tildrakizumab	*

Tralokinumab	7
Ustekinumab	160

2. How many patients were treated by the **Dermatology** or **Rheumatology** Departments or Clinics with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications by the Dermatology and Rheumatology departments, during the period 1 April to 30 June 2026.

Drug Name	Number of patients treated by the Dermatology Department	Number of patients treated by the Rheumatology Department
Adalimumab	108	357
Apremilast	7	22
Baricitinib	0	43
Bimekizumab	*	7
Brodalumab	*	0
Certolizumab Pegol	0	39
Etanercept	*	167
Guselkumab	*	0
Infliximab	0	19
Ixekizumab	0	5
Risankizumab	40	9
Secukinumab	38	62
Ustekinumab	26	15

3. How many patients with **Plaque Psoriasis** or **Psoriatic Arthritis** across all departments were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications for Plaque Psoriasis and Psoriatic Arthritis, during the period 1 April to 30 June 2026.

Drug Name	Number patients with Plaque Psoriasis	Number patients with Psoriatic Arthritis
Adalimumab	90	80
Bimekizumab	*	*
Secukinumab	34	40
Apremilast	7	21
Certolizumab Pegol	0	0
Etanercept	*	27
Guselkumab	*	0
Infliximab	*	7

Ixekizumab	0	*
Risankizumab	37	5
Ustekinumab	24	14
Brodalumab	*	0
Deucravacitinib	0	0

4. How many patients with **Atopic Dermatitis** across all departments were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications for Atopic Dermatitis, during the period 1 April to 30 June 2026.

Drug Name	Atopic Dermatitis
Baricitinib	0
Dupilumab	141
Nemolizumab	*

5. How many patients with **Hidradenitis Suppurativa** across all departments were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications for Hidradenitis Suppurativa, across all departments, during the period 1 April to 30 June 2026.

Drug Name	Hidradenitis Suppurativa
Adalimumab	17
Bimekizumab	0
Secukinumab	6

FOI.21176

6. How many patients were treated in **total** regardless of diagnosis with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications, for any condition, during the period 1 April to 30 June 2026.

Drug Name	Total number of patients treated regardless of diagnosis
Adalimumab	618
Etrasimod	*
Filgotinib	30
Golimumab	25
Guselkumab	*
Infliximab	226

Mirikizumab	0
Ozanimod	*
Risankizumab	170
Tofacitinib	8
Upadacitinib	134
Ustekinumab	160
Vedolizumab	217

7. How many patients were treated by the **Gastroenterology** Department or Clinic with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated by the Gastroenterology Department with the listed medications, during the period 1 April to 30 June 2026.

Drug Name	Number of patients treated by the Gastroenterology Department
Adalimumab	151
Etrasimod	*
Filgotinib	12
Golimumab	0
Guselkumab	*
Infliximab	106
Mirikizumab	0
Ozanimod	*
Risankizumab	106
Tofacitinib	*
Upadacitinib	89
Ustekinumab	116
Vedolizumab	155

8. How many patients with **Crohn's Disease, Ulcerative Colitis** or **Inflammatory Bowel Disease NOS** in total regardless of department / clinic, were treated with the following drugs between **1st April 2026 and 30th June 2026**, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications for Crohn's Disease, Ulcerative Colitis and Inflammatory Bowel Disease NOS, by any department, during the period 1 April to 30 June 2026.

Drug Name	Number patients with Crohn's Disease	Number patients with Ulcerative Colitis	Number patients with Inflammatory Bowel Disease NOS
Adalimumab	136	17	*
Etrasimod	0	*	0
Filgotinib	0	12	0
Golimumab	0	0	0

Guselkumab	*	0	0
Infliximab	104	71	*
Mirikizumab	0	0	0
Ozanimod	0	*	0
Risankizumab	102	22	0
Tofacitinib	0	*	0
Upadacitinib	28	60	*
Ustekinumab	71	46	*
Vedolizumab	64	146	6

FOI.21177

9. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

The UHB provides within the table below, the number of people treated with the listed medications, for any condition, during the period 1 April to 30 June 2026.

Name of medicine	Number patients treated
Benralizumab (Fasenra)	82
Depemokimab (Exdensur)	0
Dupilumab (Dupixent)	158
Mepolizumab (Nucala)	24
Omalizumab (Xolair)	*
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	170

10. How many patients were treated for **severe asthma**, **COPD**, **CRwNP** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

The UHB provides within the table below, the number of patients treated with the listed medications for Severe Asthma, COPD and CRwNP, during the period 1 April to 30 June 2026.

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
Benralizumab (Fasenra)	80		
Depemokimab (Exdensur)	0		0
Dupilumab (Dupixent)	15	0	*
Mepolizumab (Nucala)	24	0	0
Omalizumab (Omyclo)	5		0
Reslizumab (Cinqaero)	0		
Tezepelumab (Tezspire)	170		0

11. How many patients were treated for **Atopic Dermatitis** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

The UHB provides within the table below, the number of patients treated with Dupilumab (Dupixent) for Atopic Dermatitis, during the period 1 April to 30 June 2026.

Name of medicine	Number of patients with Atopic Dermatitis	Number of patients with Chronic Spontaneous Urticaria (CSU)
Dupilumab (Dupixent)	141	0

12. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

The UHB provides within the table below, the number of patients treated by the Respiratory, Dermatology and other departments, with the listed medications, during the period 1 April to 30 June 2026.

Name of medicine	Respiratory departments	Dermatology departments	Other departments
Benralizumab (Fasenra)	67	0	15
Depemokimab (Exdensur)	0	0	0
Dupilumab (Dupixent)	12	145	*
Mepolizumab (Nucala)	21	0	*
Omalizumab (Xolair)	0	*	*
Reslizumab (Cinqaero)	0	0	0
Tezepelumab (Tezspire)	144	0	26